ReviewHead and neck pathology2013
Sclerosing polycystic adenosis of salivary glands: a review with some emphasis on intraductal epithelial proliferations.
Review in Head and neck pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 41 citations in OpenAlex.
- Imaging of benign salivary gland tumors under the fifth WHO classification, with a focus on rare histologic types and newly listed entities-Part II.Japanese journal of radiology · 2026Review
- Article
- Sclerosing polycystic adenosis arising in the parotid gland with trismus: a case report and literature review.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2022Article
- Sclerosing Polycystic Adenosis Arising in the Parotid Gland Without PI3K Pathway Mutations.Head and neck pathology · 2022Article
- Case of labial sclerosing polycystic adenoma with ductal carcinoma in situ (DCIS).BMJ case reports · 2021Article
- Intraductal Carcinoma of Salivary Glands Harboring TRIM27-RET Fusion with Mixed Low Grade and Apocrine Types.Head and neck pathology · 2020Article
- [Updates on tumours of the salivary glands : 2017 WHO classification].Der Pathologe · 2018Review
- Newly described salivary gland tumors.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Review
- Surgical Treatment of Rare Sclerosing Polycystic Adenosis of the Deep Parotid Gland.Plastic and reconstructive surgery. Global open · 2016Article
- Sclerosing Polycystic Adenosis: A Rare Tumor of the Salivary Glands.The Permanente journal · 2016Article
- Foamy cell (hibernoma-like) change is a rare histopathological feature in renal cell carcinoma.Virchows Archiv : an international journal of pathology · 2014Article
- Salivary gland tumor "wishes" to add to the next WHO Tumor Classification: sclerosing polycystic adenosis, mammary analogue secretory carcinoma, cribriform adenocarcinoma of the tongue and other sites, and mucinous variant of myoepithelioma.Head and neck pathology · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sclerosing polycystic adenosis (SPA) is a rare condition of salivary glands. The most common site is the parotid gland (80 % of cases). SPA shows no gender predilection and occurs over a wide age spectrum (9-84 years). SPA is mostly unifocal, but may rarely be multifocal. Histologically, SPA are sharply circumscribed mostly unencapsulated lesions composed of acinar and ductal components with variable cytomorphological characteristics, including foamy, vacuolated, apocrine, mucous, clear/ballooned, squamous, columnar and oncocyte-like cells. Characteristic for SPA is the presence of large acinar cells with abundant eosinophilic cytoplasmic granules. The stroma is densely collagenized, frequently harbouring a variably intense chronic inflammatory infiltrate and may contain fat. Rarely the stroma is myxoid. Some degree of intraductal epithelial proliferations have been reported in at least 50 % of cases. The proportion of cases with epithelial proliferations that fulfill criteria for high-grade ductal carcinoma in-situ is <10 %. Immunohistochemically, both ductal and acinar cells are positive for broad spectrum cytokeratins. There is variable immunoreactivity for epithelial membrane antigen and S-100 protein. CEA, p53 and HER2 is reportedly negative. Gross cystic disease fluid protein-15 is strongly expressed in the acinar component. There is consistent but variable expression of estrogen and progesterone receptors. The proliferative index (Ki-67) is low (1-2 %) in the benign (acinar and ductal) components. Using HUMARA methodology (non-random inactivation of X-chromosomes), six cases with atypical epithelial proliferations have been shown to be clonal processes. Recurrences have been reported in up to 19 % of cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.